340 related articles for article (PubMed ID: 27449897)
21. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
22. Plasmodium chabaudi chabaudi and P. falciparum: inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin.
Nankya-Kitaka MF; Curley GP; Gavigan CS; Bell A; Dalton JP
Parasitol Res; 1998 Jul; 84(7):552-8. PubMed ID: 9694371
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
[TBL] [Abstract][Full Text] [Related]
24. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
[TBL] [Abstract][Full Text] [Related]
25. The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: importance of active site metal ions in the binding of substrates and inhibitors.
Maric S; Donnelly SM; Robinson MW; Skinner-Adams T; Trenholme KR; Gardiner DL; Dalton JP; Stack CM; Lowther J
Biochemistry; 2009 Jun; 48(23):5435-9. PubMed ID: 19408962
[TBL] [Abstract][Full Text] [Related]
26. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach.
Kesharwani RK; Singh DV; Misra K
J Vector Borne Dis; 2013; 50(2):93-102. PubMed ID: 23995310
[TBL] [Abstract][Full Text] [Related]
27. Identification of new promising Plasmodium falciparum superoxide dismutase allosteric inhibitors through hierarchical pharmacophore-based virtual screening and molecular dynamics.
Araujo JSC; de Souza BC; Costa Junior DB; Oliveira LM; Santana IB; Duarte AA; Lacerda PS; Dos Santos Junior MC; Leite FHA
J Mol Model; 2018 Jul; 24(8):220. PubMed ID: 30056475
[TBL] [Abstract][Full Text] [Related]
28. M17 leucine aminopeptidase of the human malaria parasite Plasmodium vivax.
Lee JY; Song SM; Seok JW; Jha BK; Han ET; Song HO; Yu HS; Hong Y; Kong HH; Chung DI
Mol Biochem Parasitol; 2010 Mar; 170(1):45-8. PubMed ID: 19931315
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development.
Stack CM; Lowther J; Cunningham E; Donnelly S; Gardiner DL; Trenholme KR; Skinner-Adams TS; Teuscher F; Grembecka J; Mucha A; Kafarski P; Lua L; Bell A; Dalton JP
J Biol Chem; 2007 Jan; 282(3):2069-80. PubMed ID: 17107951
[TBL] [Abstract][Full Text] [Related]
30. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
[TBL] [Abstract][Full Text] [Related]
31. Active site metals mediate an oligomeric equilibrium in Plasmodium M17 aminopeptidases.
Malcolm TR; Belousoff MJ; Venugopal H; Borg NA; Drinkwater N; Atkinson SC; McGowan S
J Biol Chem; 2021; 296():100173. PubMed ID: 33303633
[TBL] [Abstract][Full Text] [Related]
32. Mapping the Pathway and Dynamics of Bestatin Inhibition of the Plasmodium falciparum M1 Aminopeptidase PfA-M1.
Yang W; Riley BT; Lei X; Porebski BT; Kass I; Buckle AM; McGowan S
ChemMedChem; 2018 Dec; 13(23):2504-2513. PubMed ID: 30318749
[TBL] [Abstract][Full Text] [Related]
33. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
[TBL] [Abstract][Full Text] [Related]
34. Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.
Spicer T; Fernandez-Vega V; Chase P; Scampavia L; To J; Dalton JP; Da Silva FL; Skinner-Adams TS; Gardiner DL; Trenholme KR; Brown CL; Ghosh P; Porubsky P; Wang JL; Whipple DA; Schoenen FJ; Hodder P
J Biomol Screen; 2014 Aug; 19(7):1107-15. PubMed ID: 24619116
[TBL] [Abstract][Full Text] [Related]
35. In silico Screening for Identification of Novel Anti-malarial Inhibitors by Molecular Docking, Pharmacophore Modeling and Virtual Screening.
Batool S; Khan ZA; Kamal W; Mushtaq G; Kamal MA
Med Chem; 2015; 11(7):687-700. PubMed ID: 25741881
[TBL] [Abstract][Full Text] [Related]
36. Multiple e-pharmacophore modelling pooled with high-throughput virtual screening, docking and molecular dynamics simulations to discover potential inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH).
Saxena S; Durgam L; Guruprasad L
J Biomol Struct Dyn; 2019 Apr; 37(7):1783-1799. PubMed ID: 29718775
[TBL] [Abstract][Full Text] [Related]
37. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.
Lukens AK; Heidebrecht RW; Mulrooney C; Beaudoin JA; Comer E; Duvall JR; Fitzgerald ME; Masi D; Galinsky K; Scherer CA; Palmer M; Munoz B; Foley M; Schreiber SL; Wiegand RC; Wirth DF
J Infect Dis; 2015 Apr; 211(7):1097-103. PubMed ID: 25336726
[TBL] [Abstract][Full Text] [Related]
38. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Traditional Chinese Medicine Derived Compounds as Wild Type and Mutant Plasmodium falciparum Dihydrofolate Reductase Inhibitors: Induced Fit Docking and ADME Studies.
Iwaloye O; Elekofehinti OO; Kikiowo B; Fadipe TM; Akinjiyan MO; Ariyo EO; Aiyeku OO; Adewumi NA
Curr Drug Discov Technol; 2021; 18(4):554-569. PubMed ID: 32729419
[TBL] [Abstract][Full Text] [Related]
40. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
Pandey RK; Narula A; Naskar M; Srivastava S; Verma P; Malik R; Shah P; Prajapati VK
J Biomol Struct Dyn; 2017 Mar; 35(4):791-804. PubMed ID: 26984239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
